Mizagliflozin

DB19036InvestigationalSmall molecule

Mizagliflozin is under investigation in clinical trial NCT05721729 (Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions).

Mechanism: Pharmacologically active on Sodium/glucose cotransporter 1
Curator reviewed
Formula / weight: C₂₈H₄₄N₄O₈ · 564.68 g/mol (avg)
Also known as: 3-((3-(4-((3-(.beta.-d-glucopyranosyloxy)-5-(propan-2-yl)-1h-pyrazol-4-yl)methyl)-3-methylphenoxy)propyl)amino)-2,2-dimethylpropanamide · Propanamide, 3-((3-(4-((3-(.beta.-d-glucopyranosyloxy)-5-(1-methylethyl)-1h-pyrazol-4-yl)methyl)-3-methylphenoxy)propyl)amino)-2,2-dimethyl-
Code names: Dsp-3235 free base · GSK-1614235 free base · Kga-3235 free base

Resolves to

Compound

UNII1X96A704XVCAS666843-10-3

Structure

InChIKeyLREHMKLEOJAVMQ-TXKDOCKMSA-NSMILESCC(C)C1=C(CC2=CC=C(OCCCNCC(C)(C)C(N)=O)C=C2C)C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=NN1

Targets

P13866SLC5A1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mizagliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account